|
Daily Medical Update
Herpes Zoster & Post-Herpetic Neuralgia
Wednesday, March 18, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Frontiers in Pharmacology (2025) - Systematic Review/Meta-analysis
Key Findings
- Across 21 RCTs (n=1,478), adjunctive Liu Shen Wan vs conventional treatment alone shortened vesicle cessation by MD -1.44 days and scab formation by MD -1.72 days.
- Combination therapy reduced PHN incidence (RR 0.24, 95% CI 0.10-0.57) and adverse reactions (RR 0.60, 95% CI 0.37-0.96) versus conventional care.
📋 Practice Implication: If a patient is already using this adjunctive approach, discuss that pooled data suggest faster lesion recovery and lower PHN risk, but frame certainty as moderate due to heterogeneous trial quality.
|
Frontiers in Neurology (2025) - Network Meta-analysis
Key Findings
- In 9 RCTs (n=741), paravertebral block (PVB)-based regimens ranked above ESPB regimens for total treatment effectiveness versus comparator approaches in thoracic zoster.
- For pain outcomes, PVB regimens showed greater VAS reduction versus ESPB comparators across the network analysis.
📋 Practice Implication: For severe thoracic zoster pain, early referral to pain specialists for PVB-capable pathways may improve short-term pain outcomes and potentially reduce downstream PHN burden.
|
JAMA Ophthalmology (2025) - Randomized Controlled Trial
Key Findings
- In HZO participants with PHN, valacyclovir 1 g/day vs placebo did not lower PHN prevalence at 12 months (38% vs 40%; P>.99).
- Valacyclovir was associated with lower neuropathic medication dose at 12 months (271 vs 363 mg/day; P=0.006) and shorter pain duration at 18 months (difference -3.39 months; P=0.046).
📋 Practice Implication: In selected HZO patients with persistent neuropathic pain, extended valacyclovir can be considered to reduce analgesic burden even when prevalence endpoints are unchanged.
|
Journal of the College of Physicians and Surgeons Pakistan (2025) - Randomized Controlled Trial
Key Findings
- Hydromorphone+dexmedetomidine PCIA plus baseline therapy reduced NRS pain more than oral tramadol at 1 and 4 weeks (p<0.001), with a persistent difference at 12 weeks (p=0.003).
- The intervention arm had lower HZ-related pain frequency and better PSQI sleep outcomes, although drowsiness occurred more often vs control (p<0.05).
📋 Practice Implication: For refractory acute zoster pain not controlled with oral regimens, short-course monitored PCIA pathways may improve pain trajectory and sleep while requiring sedation surveillance.
|
CNS Neuroscience & Therapeutics (2025) - Randomized Crossover Trial
Key Findings
- Both duloxetine+pregabalin and amitriptyline+pregabalin improved PHN pain from baseline (p<0.001), with similar ≥50% pain relief rates (52% vs 48%).
- Dry mouth was lower with duloxetine vs amitriptyline (11% vs 26%; p=0.008), while overall analgesic efficacy was comparable.
📋 Practice Implication: When combining with pregabalin, duloxetine is a reasonable first choice in older adults or anticholinergic-sensitive patients because efficacy is similar but tolerability favors duloxetine.
|
European Respiratory Review (2026) - Systematic Review/Meta-analysis
Key Findings
- COPD was associated with higher herpes zoster risk vs non-COPD populations (pooled RR 1.49), and corticosteroid-treated COPD had further elevated risk (RR 1.86).
- Among patients with herpes zoster, COPD increased PHN risk (rate ratio 1.50) and was linked to greater healthcare utilization.
📋 Practice Implication: Use COPD status, especially steroid exposure, as a trigger for proactive recombinant zoster vaccination counseling and lower thresholds for early antiviral treatment and close pain follow-up.
|
Clinical Microbiology and Infection (2025) - Phase 3 Randomized Controlled Trial
Key Findings
- In 25,000 adults aged ≥40 years, live attenuated vaccine lowered HZ incidence vs placebo (5.3 vs 12.6 per 1000 person-years), with overall efficacy 57.6%.
- Efficacy was highest in ages 50-69 (~63-64%), and most solicited adverse events were mild/moderate (13.8% vaccine vs 5.1% placebo).
📋 Practice Implication: Where this vaccine is available, offer age-targeted prevention discussions now rather than waiting for incident disease, while still preferring recombinant zoster vaccine when guideline-concordant access exists.
|
|
Recent evidence for herpes zoster and post-herpetic neuralgia supports early risk-stratified prevention and aggressive pain control, with the strongest data coming from meta-analyses and randomized trials. Interventional analgesic strategies and selected antiviral suppression approaches can reduce pain burden or medication intensity in specific subgroups, while vaccine and comorbidity data reinforce prevention-first planning in primary care. For PCP practice, the highest-yield actions are vaccination, rapid treatment of acute zoster pain, and targeted follow-up for high-risk patients (older age and chronic comorbidity).
|
|